Pharmacoeconomic properties of disease-modifying antirheumatic drugs
The discipline of pharmacoeconomics has gained in importance in recent decades as countries and healthcare payers face pressures to justify investments in healthcare innovations. This situation has largely resulted from a coincidence of a demographic shift towards an increasingly elderly population and the development of effective and much more expensive therapies based in biotechnological advances. Many of these therapies improve health and may increase productivity and possibly prevent costly complications. Consequently health expenditures, previously considered “expenses”, are now more frequently referred to as “investments” to maintain a healthy and productive workforce . Demonstration of “value for money” has become an important milestone for therapies on their way to rapid, and reimbursed, adoption.
KeywordsRheumatoid Arthritis Health Assessment Questionnaire Health Assessment Questionnaire Score Pharmacoeconomic Evaluation Rheumatoid Arthri
Unable to display preview. Download preview PDF.
- 8.Laupacis A, Feeny D, Detsky AS, Tugwell PX (1992) How attractive does a new tech-nology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 146: 473–481Google Scholar
- 12.Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-Effectiveness in Health and Medicine. Oxford University Press, New York, OxfordGoogle Scholar
- 15.O’Brien BJ, Heyland D, Richardson WS, Levine M, Drummond MF (1997) Users’ guides to the medical literature. XIII. How to use an article on economic analysis of clin-ical practice. B. What are the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group, [erratum appears in JAMA (1997) Oct 1; 278 (13): 1064]. JAMA 277 (22): 1802-1806Google Scholar
- 16.Drummond MF, Richardson WS, O’Brien BJ, Levine M, Heyland D (1997) Users’ guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 277 (19): 1552–1557CrossRefPubMedGoogle Scholar
- 28.Clarke AE, Penrod J, St Pierre Y, Petri MA, Manzi S, Isenberg DA, Gordon C, Senecal JL, Fortin PR, Sutcliffe N et al (2000) Underestimating the value of women: assessing the indirect costs of women with systemic lupus erythematosus. Tri-Nation Study Group. J Rheumatol 27 (11): 2597–2604PubMedGoogle Scholar